PMID- 35276381
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20221207
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Print)
IS  - 1201-9712 (Linking)
VI  - 118
DP  - 2022 May
TI  - Adverse events following COVID-19 vaccination in South Korea between February 28 
      and August 21, 2021: A nationwide observational study.
PG  - 173-182
LID - S1201-9712(22)00145-X [pii]
LID - 10.1016/j.ijid.2022.03.007 [doi]
AB  - OBJECTIVES: To investigate the clinical characteristics of adverse events (AEs) 
      after COVID-19 vaccination in patients in South Korea. DESIGN: Data from the 
      Korean Disease Control and Prevention Agency on AEs from 4 COVID-19 vaccines, 
      including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26, 2021, 
      to August 21, 2021, were assessed. The epidemiological characteristics, clinical 
      symptoms, severity, complications, and mortality were descriptively analyzed. 
      RESULTS: Overall, 36.3 million individuals who completed the COVID-19 vaccination 
      doses during the study period were included, and 153,183 AEs were reported. Most 
      AEs occurred after the first dose (80.6%) and within a day (63.2%) after 
      vaccination. Of the AEs, 95.5% were nonsevere cases; however, 4.5% were severe. 
      Most mild AEs showed a similar frequency across all age groups, but major severe 
      AEs and mortality events increased with age. CONCLUSIONS: Although there were 
      differences in the frequency of occurrence, various adverse reactions were 
      confirmed in using all 4 COVID-19 vaccines, even with the BNT162b2 
      (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be 
      continuously conducted.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Lee, Dong Seok
AU  - Lee DS
AD  - Department of Internal Medicine, Seoul National University Boramae Medical 
      Center, Seoul National University College of Medicine, Seoul, Korea. Electronic 
      address: easeagle@naver.com.
FAU - Kim, Ji Won
AU  - Kim JW
AD  - Department of Internal Medicine, Seoul National University Boramae Medical 
      Center, Seoul National University College of Medicine, Seoul, Korea. Electronic 
      address: kjwjor@snu.ac.kr.
FAU - Lee, Kook Lae
AU  - Lee KL
AD  - Department of Internal Medicine, Seoul National University Boramae Medical 
      Center, Seoul National University College of Medicine, Seoul, Korea. Electronic 
      address: kllee@brmh.org.
FAU - Jung, Yong Jin
AU  - Jung YJ
AD  - Department of Internal Medicine, Seoul National University Boramae Medical 
      Center, Seoul National University College of Medicine, Seoul, Korea. Electronic 
      address: jyj0601@snu.ac.kr.
FAU - Kang, Hyoun Woo
AU  - Kang HW
AD  - Department of Internal Medicine, Seoul National University Boramae Medical 
      Center, Seoul National University College of Medicine, Seoul, Korea. Electronic 
      address: gangmali@naver.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220309
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the 
      International Society for Infectious Diseases
JID - 9610933
RN  - JT2NS6183B (Ad26COVS1)
RN  - 0 (COVID-19 Vaccines)
RN  - B5S3K2V0G8 (ChAdOx1 nCoV-19)
RN  - N38TVC63NU (BNT162 Vaccine)
SB  - IM
MH  - Ad26COVS1
MH  - BNT162 Vaccine
MH  - *COVID-19/epidemiology/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - ChAdOx1 nCoV-19
MH  - Humans
MH  - Republic of Korea/epidemiology
MH  - SARS-CoV-2
MH  - Vaccination/adverse effects
PMC - PMC8904009
OTO - NOTNLM
OT  - COVID-19 vaccines
OT  - SARS-CoV-2
OT  - adverse events
OT  - vaccine reactions
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/03/12 06:00
MHDA- 2022/04/29 06:00
PMCR- 2022/03/09
CRDT- 2022/03/11 20:11
PHST- 2021/10/26 00:00 [received]
PHST- 2022/02/14 00:00 [revised]
PHST- 2022/03/04 00:00 [accepted]
PHST- 2022/03/12 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
PHST- 2022/03/11 20:11 [entrez]
PHST- 2022/03/09 00:00 [pmc-release]
AID - S1201-9712(22)00145-X [pii]
AID - 10.1016/j.ijid.2022.03.007 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2022 May;118:173-182. doi: 10.1016/j.ijid.2022.03.007. Epub 
      2022 Mar 9.